跳至主要内容
临床试验/ACTRN12618001240235
ACTRN12618001240235撤回3 期

For people with Dupuytren's disease of the hand, is treatment with percutaneous fasciotomy as effective as injectable collagenase in improving functionality and fixed flexure angles.

aunceston General Hospital0 个研究点目标入组 100 人开始时间: 2018年7月23日最近更新:

试验速览

阶段
3 期
状态
撤回
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Dupuytren’s disease with contracture (20-100 degrees Metacarpo-phalyngeal (MCP) joint or 20-80 at the proximal interphalyngeal (PIP) joint.)
  • Consulting clinician deems it appropriate management for the patient to have one or other of the fasciotomy procedures
  • No previous treatment within 90 days
  • Able to provide informed consent; age 18 years and older

排除标准

  • Bleeding disorder, blood thinning treatment (except aspirin 150mg/day)
  • Allergy to collagenase ; pregnancy, breast feeding; neuromuscular disorders
  • Administration of tetracyclines, antracyclines or anthraquinones in the past 14 days (these meds inhibit matrix metalloproteinase-mediate collagen degradation at suprapharmacological concentrations in vitro).

研究者

发起方
aunceston General Hospital

相似试验